- Home
- BRT vs CNTX Comparison
BRT vs CNTX Comparison
Compare BRT & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | CNTX |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 283.9M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRT | CNTX |
|---|---|---|
| Price | $14.23 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $19.75 | $6.60 |
| AVG Volume (30 Days) | 65.4K | ★ 747.3K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.04% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $0.49 |
| 52 Week High | $16.69 | $3.62 |
Technical Indicators
Market Signals| Indicator | BRT | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 41.64 |
| Support Level | $13.18 | $2.07 |
| Resistance Level | $15.02 | $2.58 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 57.26 | 12.10 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.